Hikma Pharmaceuticals PLC (LSE:HIK) agreed to acquire Finished Dosage Form Business and Assets of Xellia Pharmaceuticals for approximately $190 million on June 17, 2024. A cash consideration of $135 million will be paid by Hikma Pharmaceuticals PLC and an additional contingent consideration of up to $50 million cash, subject to the achievement of certain regulatory and commercial milestones. As a part of transaction, US finished dosage form business and assets, including a commercial portfolio and pipeline of differentiated products, a manufacturing facility in Cleveland, Ohio, sales and marketing capabilities, and an R&D center in Zagreb, Croatia will be acquired.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,875 GBX | -2.19% |
|
-6.25% | +4.81% |
24/06 | Teva launches generic version of Novo Nordisk's diabetes drug Victoza | RE |
20/06 | Fitch Confirms Ratings, Outlook on Hikma Pharmaceuticals on 'Defensive Market Position' | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+4.81% | 526.07Cr | |
+55.95% | 82TCr | |
+43.62% | 64TCr | |
-6.98% | 35TCr | |
+19.08% | 33TCr | |
+9.05% | 30TCr | |
+16.30% | 24TCr | |
+2.41% | 23TCr | |
+12.47% | 22TCr | |
+8.91% | 17TCr |
- Stock Market
- Equities
- HIK Stock
- News Hikma Pharmaceuticals PLC
- Hikma Pharmaceuticals PLC agreed to acquire Finished Dosage Form Business and Assets of Xellia Pharmaceuticals for approximately $190 million.